Detalhe da pesquisa
1.
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Blood
; 139(18): 2747-2757, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511184
2.
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031755
3.
Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study.
Am J Hematol
; 98(2): 264-271, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588407
4.
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
Blood
; 135(18): 1531-1540, 2020 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32108228
5.
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape
Haematologica
; 106(12): 3056-3066, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054115
6.
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.
Eur J Haematol
; 107(1): 111-121, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33765335
7.
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
Haematologica
; 104(1): 138-146, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30171024
8.
BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Ann Hematol
; 98(8): 1973-1980, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31111177
9.
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Blood
; 127(21): 2569-74, 2016 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27002117
10.
Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
Am J Hematol
; 90(11): 986-91, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26214580
11.
Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma.
Biol Blood Marrow Transplant
; 19(3): 445-9, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23186983
12.
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).
Blood
; 115(1): 32-7, 2010 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-19884643
13.
An incidental finding of maternal multiple myeloma by non invasive prenatal testing.
Prenat Diagn
; 37(12): 1257-1260, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29023902
14.
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Bone Marrow Transplant
; 57(6): 966-974, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35422077
15.
[Biclonal or biphenotypic chronic lymphotic leukemia? An answer brought by the treatment]. / Leucémie lymphoïde chronique biclonale ou biphénotypique ? Une réponse par le traitement.
Ann Biol Clin (Paris)
; 69(3): 325-30, 2011.
Artigo
em Francês
| MEDLINE | ID: mdl-21659049
16.
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Leukemia
; 35(8): 2332-2345, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33483613
17.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Lancet Haematol
; 7(12): e874-e883, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33242444
18.
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
J Clin Oncol
; 37(31): 2815-2824, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31339826
19.
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.
Clin Cancer Res
; 25(14): 4224-4230, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31053600
20.
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Lancet
; 370(9594): 1209-18, 2007 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-17920916